In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lucie Ellis

Lucie Ellis, based in the UK, joined the SCRIP Intelligence team in 2012. In her current position as a Creative Content Reporter, she is focused on introducing innovative and imaginative ways to display content on the web and routinely annoys SCRIP’s technology and design teams by thinking too far outside of the box. As a reporter covering the pharma and biotech world, Lucie understandably spends a lot of her time writing about drugs and money or Googling abbreviations. However she has a particular interest in employment trends, social and digital media use by industry, patient-centricity, big data, and clinical research in the metabolic and CNS fields. Lucie enjoys traveling and can often be seen out and about at industry events across the globe as SCRIP’s roving reporter.
Advertisement
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q

Sanofi is seeking asset deals to bulk up its oncology pipeline in 2017 – specifically, the big pharma is on the lookout for oncology compounds with potential in prostate cancer or breast cancer, the company highlighted during its first-quarter earnings call.

Deals Business Strategies

Bayer Ups Guidance While Pharma Head Highlights NHL Drug Copanlisib

Bayer has initiated the regulatory filing process in the US for its pipeline non-Hodgkin's lymphoma drug copanlisib, head of pharma Dieter Weinand said during the company's first quarter earnings call during which the German group also said it was upping guidance for the year.

Business Strategies Cancer

Celyad VP On IP Issues, Development Timelines For CAR-T Therapies

Georges Rawadi, vice president of business development and intellectual property at Celyad, talks to Scrip on the sidelines of the recent BIO-Europe Spring partnering conference in Barcelona about the company's pipeline of CAR-T therapies and recently resolved patent disputes for its technology.

StartUps and SMEs Intellectual Property

Can Barlow Flip E-Therapeutics From A Miss To A Hit?

Dr Raymond Barlow, the newly appointed CEO of e-Therapeutics, is hoping he can turn the lackluster business around and reposition it as a show stealing co-star for efficient drug discovery partnering, utilizing its bioinformatics platform technology.

Business Strategies StartUps and SMEs

Pfizer Gets First Regulatory Nod For Besponsa

Pfizer's acute lymphocytic leukemia therapy Besponsa has received a positive recommendation in Europe, which should lead to the drug's first approval worldwide and will add to the high expectations for its regulatory outcome in the US later this year.

Approvals Policy & Regulation

Noxxon CEO Talks Partnering Strategy & Cancer Combos

Aram Mangasarian, CEO of Noxxon Pharma, a biotech company focused on cancer therapies targeting the tumor microenvironment, discusses partnering options and his strategy for how Noxxon can compete in the busy immuno-oncology space.

StartUps and SMEs Cancer
See All
Advertisement
UsernamePublicRestriction

Register